Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: J Addict Dis. 2021 Aug 25;40(2):192–196. doi: 10.1080/10550887.2021.1967688

Receipt of preventive health services and current cannabis users

Emily Lum a, Sri Lekha Tummalapalli b, Meena Khare a, Salomeh Keyhani c,d
PMCID: PMC8873237  NIHMSID: NIHMS1752491  PMID: 34433384

Abstract

Substance use is associated with greater barriers and reduced access to care. Little research, however, has examined the relationship between cannabis use and receipt of preventive health services. Using data from the 2017 Behavioral Risk Factor Surveillance System, we examined the association between current cannabis use and receipt of 12 preventive health services, adjusting for sociodemographic characteristics and access to care. In analyses that adjusted for sociodemographic factors and access to care, participants with current cannabis use had lower odds of being vaccinated for influenza (AOR = 0.67, 95% CI = 0.54–0.83) and higher odds of ever receiving HPV vaccination (AOR = 1.77, 95% CI = 1.06–2.96) and HIV screening (AOR = 2.34, 95% CI = 1.88–2.92) compared with those without cannabis use. Among the 12 preventive services examined, we found three differences in receipt of preventive services by cannabis use status. Cannabis use does not appear to be associated with significant underuse of preventive services.

Keywords: Cannabis, preventive health services, Marijuana

Introduction

Cannabis is legal for some form of use in 33 states and Washington, D.C. Legalization has been accompanied by increased cannabis use. Between 2001–2002 and 2012–2013, past year cannabis use doubled from 4.1% to 9.5% in U.S. adults.1 A 2017 study found that approximately 15% and 8% of U.S. adults had used cannabis in the past year and past 30 days, respectively.2

Prior research has demonstrated that heavy use of alcohol and/or drugs is associated with greater barriers and reduced access to health care.3 No studies to date have examined the association of cannabis use with access to care. Cannabis has adverse neurocognitive effects, including decreased functional connectivity, activity, and volume in regions of the brain associated with learning, memory, and inhibitory control.4 Persistent cannabis use is associated with memory problems, difficulty managing activities of daily living, and amotivation.5,6 Cannabis use also has mental health effects, including an association with psychosis, treatment relapse for depression, and avoidance of social situations in those with social anxiety.4,7

The social, neurocognitive, and mental health effects of cannabis may be associated with less engagement with health care services. Little research, however, has examined the relationship between cannabis use and health promoting behaviors such as obtaining preventive care. Therefore, in this study, we examined the association of current cannabis use with receipt of preventive health services.

Methods

We used data from the 2017 Behavioral Risk Factor Surveillance System (BRFSS). We included states that participated in both the optional Marijuana Module and other optional modules on cardiovascular health, vaccinations, alcohol screening, and diabetes. Our predictor was current cannabis use, as assessed by the question “During the past 30 days, on how many days did you use marijuana or hashish?” We examined uptake of 12 preventive services, including cardiovascular risk reduction strategies, vaccinations, health behavior screenings, and diabetes care (Table 2). We used recommended guidelines from the U.S. Preventive Services Task Force (USPSTF), the Centers for Disease Control and Prevention (CDC), or the American Diabetes Association (ADA) to determine eligible participants (Table 2). Using chi-squared statistics and logistic regression, we examined whether participants who had used cannabis in the past 30 days were more or less likely than those who did not use cannabis to receive preventive health services. We adjusted for sociodemographic characteristics, including age, sex, race/ethnicity, employment, education, marital status, and access to care (insurance status and having a personal doctor).

Table 2.

Comparison of receipt of preventive health measures in participants with and without current cannabis use.

Preventive health service Numerator Denominator Current cannabis use (unweighted n = 3169, weighted N = 4880798) (%) No cannabis use (unweighted n = 53755, weighted N = 40774443) (%) p-Value Unadjusted OR (95% CI) Adjusted ORa (95% CI)
Cardiovascular risk reduction
Serum cholesterol screeningb Cholesterol checked in past 5 years Participants age 40–75 88.7 93.7 0.001 0.53 (0.36, 0.78) 0.81 (0.54, 1.21)
Serum cholesterol checkedb Cholesterol checked in past 5 years Participants age 40–75 years with hx of HTN, HLD, or CVD 85.3 91.0 0.006 0.57 (0.38, 0.86) 0.84 (0.57, 1.24)
Aspirin useb,c Regular aspirin use Participants age 50–69 years excluding if aspirin is unsafe 39.5 40.2 0.91 0.97 (0.57, 1.65) 1.07 (0.60, 1.91)
Vaccination
Influenza vaccination Influenza vaccination in past year All participants 25.4 41.5 <0.001 0.48 (0.40, 0.59) 0.67 (0.54, 0.83)
Pneumonia vaccination Pneumonia vaccination ever Participants age ≥65 70.2 72.5 0.69 0.90 (0.52, 1.55) 0.95 (0.55, 1.65)
Tetanus vaccine Tetanus vaccination since 2005 All participants 32.6 36.6 0.26 0.84 (0.62, 1.14) 0.78 (0.56, 1.1)
HPV vaccination HPV vaccination ever Participants age 18–26 40.5 36.6 0.47 1.18 (0.75, 1.85) 1.77 (1.06, 2.96)
Other health screening
Blood sugar checkedb Test for high blood sugar or diabetes in past 3 years Participants age 40–70 years who are overweight or obese 41.5 58.0 <0.001 0.51 (0.44, 0.60) 0.88 (0.73, 1.05)
Alcohol use screeningb Asked if you drink alcohol during checkup All participants 87.4 78.0 0.001 1.96 (1.30, 2.97) 1.56 (0.99, 2.46)
HIV test or screeningd Ever tested for HIV Participants age 18–65 63.2 43.2 <0.001 2.26 (1.86, 2.75) 2.34 (1.88, 2.92)
Diabetes care (among participants with diabetes only)
Serum cholesterol checkede Cholesterol checked in past 5 years History of DM 93.5 95.8 0.40 0.63 (0.21, 1.86) 1.97 (0.41, 9.55)
HbA1c checkede HbA1c measured in past year History of DM 27.1 12.0 0.042 2.73 (0.99, 7.53) 2.22 (0.97, 5.09)
Foot exama Foot exam in past year History of DM 33.7 33.3 0.97 1.02 (0.44, 2.32) 1.62 (0.68, 3.88)
Eye exama Dilated eye exam in past year History of DM 48.8 57.8 0.37 0.70 (0.32, 1.54) 1.25 (0.59, 2.64)
Influenza vaccinationc Influenza vaccination in past year History of DM 35.9 56.9 0.014 0.42 (0.21, 0.87) 0.58 (0.27, 1.24)
Pneumonia vaccinationc Pneumonia vaccination ever History of DM 58.5 58.2 0.97 1.02 (0.45, 2.30) 1.96 (0.88, 4.35)
a

Adjusted for age, sex, race/ethnicity, employment, education, marital status, insurance status, and having a personal doctor.

b

“The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial” or “Supportive evidence from well-conducted cohort studies or Supportive evidence from a well-conducted case-control study” (ADA).

c

“The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small” or “Supportive evidence from poorly controlled or uncontrolled studies or Conflicting evidence with the weight of evidence supporting the recommendation” (ADA).

d

“The USPSTF recommends the service. There is high certainty that the net benefit is substantial” or “Clear evidence from well-conducted, generalizable, randomized controlled trials that are adequately powered or Supportive evidence from well-conducted randomized controlled trials that are adequately powered or Compelling nonexperimental evidence” (ADA).

e

“Expert consensus or clinical experience” (ADA).

ADA, American Diabetes Association; BRFSS, Behavioral Risk Factor Surveillance System; CVD, cardiovascular disease; DM, diabetes mellitus; HbA1C, hemoglobin A1c; HIV, human immunodeficiency virus; HPV, human papilloma virus; HLD, hyperlipidemia; HTN, hypertension; USPSTF, United States Preventative Services Task Force.

The 2017 BRFSS data are publicly available and exempt from Institutional Review Board approval.

Results

Overall, 56,924 individuals (unweighted) were included, representing 45,655,241 U.S. adults. Of those, 10.7% reported current cannabis use. Participants with cannabis use were more likely to be younger, male, unmarried, and non-Hispanic white and had fewer comorbidities compared to those who did not use cannabis (Table 1). Additionally, those with current cannabis use were less likely than those who did not use cannabis to have health insurance (84.9% vs. 88.9%, p = 0.002) or a personal doctor (64.7% vs. 78.5%, p < 0.001).

Table 1.

Comparison of characteristics of participants with and without current cannabis use.

Variable Unweighted n = 56924 Weighted N = 45655241 Current cannabis use (%) No cannabis use (%) p-Value
Age
18–29 5266 8948243 39.6 17.2 <0.001
30–49 13223 15737392 38.0 34.1
50–64 17732 11710029 15.9 26.8
≥65 20703 9259577 6.6 21.9
Sex
Male 25129 21929777 61.6 46.4 <0.001
Race/ethnicity
Non-Hispanic White 44535 25196515 58.3 55.8 <0.001
Non-Hispanic Black 5114 4753569 12.9 10.3
Hispanic 3008 9475614 18.2 21.4
Asian, Native Hawaiian, or Pacific Islander 827 4050649 5.3 9.5
Other 2359 1433773 5.2 2.9
Employed 28186 25793136 63.8 56.0 <0.001
Education level
Less than high school graduate 4099 6748417 9.6 15.5 <0.001
High school graduate 15115 11488459 28.8 24.8
College and post-doc training 37518 27246866 61.6 59.7
Married 30406 23232570 27.9 54.0 <0.001
Clinical characteristics and medical history
Obesity (BMI ≥30) 16773 12467698 22.8 30.0 <0.001
Hypertensiona 23285 14489481 23.3 32.8 <0.001
Hyperlipidemiab 20499 13488084 21.7 33.3 <0.001
Diabetesc 7722 5227443 4.5 12.3 <0.001
Cardiovascular Disease (CVD)d,e 6527 3571282 5.0 8.2 0.004
Combined above five chronic conditions
None 19312 19489603 56.1 41.1 <0.001
1 condition 15510 12191209 24.1 27.0
2 conditions 11419 7399397 11.6 16.8
3–5 conditions 10678 6573769 8.2 15.1
Insurance
Health coveragef 51944 40227767 84.9 88.9 0.002
Has a personal doctorg 46866 35024660 64.7 78.5 <0.001
a

Have you EVER been told by a doctor, nurse, or other health professional that you have high blood pressure?.

b

Have you EVER been told by a doctor, nurse, or other health professional that your blood cholesterol is high?.

c

(Ever told) you have diabetes?.

d

(Ever told) you that you had a heart attack also called a myocardial infarction?; (Ever told) you had angina or coronary heart disease?; (Ever told) you had a stroke?.

e

Includes coronary artery disease or angina, stroke, and myocardial infarction.

f

Do you have any kind of health care coverage, including health insurance, prepaid plans such as HMOs, government plans such as Medicare, or Indian Health Service?.

g

Do you have one person you think of as your personal doctor or health care provider?.

In analyses that adjusted for sociodemographic factors and access to care, participants with current cannabis use had lower odds of being vaccinated for influenza in the past year (adjusted odds ratio [AOR] = 0.67, 95% confidence interval [CI] = 0.54–0.83) and higher odds of ever receiving HPV vaccination (AOR = 1.77, 95% CI = 1.06–2.96) and HIV screening (AOR = 2.34, 95% CI = 1.88–2.92) compared with those without cannabis use. There were no statistically significant differences in receipt of serum cholesterol, alcohol use, or diabetes screenings between participants with and without current cannabis use in adjusted analyses.

Discussion and conclusions

We examined the relationship between current cannabis use and receipt of preventive services. Among the 12 services examined, participants with current cannabis use were less likely to receive influenza vaccination but more likely to receive HPV vaccination and HIV screening than those who did not use cannabis. Prior analyses have shown that those who use cannabis are more likely to engage in unprotected sex.8 This difference in health behaviors may explain why they were more likely to receive HPV vaccination and HIV screening. We also found that participants with cannabis use were less likely to have insurance coverage suggesting that access to care may also be a factor in the association between cannabis use and receipt of preventive care services.

Some limitations are noted. This study was limited to individuals in 10 states and Washington, D.C. who participated in the Marijuana Module and other select optional modules in 2017, thus potentially limiting the overall generalizability of our findings. However, the states that were included are geographically diverse. Receipt of preventive services are also by self-report. Cannabis use information was limited to the past 30 days, so we were unable to assess the relationship between cumulative cannabis use and receipt of preventive health services. Additionally, we included participants in our analysis who reported any cannabis use in the past 30 days, which may explain why we found little association between cannabis use and receipt of preventive services. An analysis limited to daily use in the past 30 days may demonstrate a different relationship. Finally, we did not account for the use of other substances in the analysis. However, this is an important relationship to examine in future work as people with more frequent cannabis use are more likely to use other substances9 and use of other substances is associated with lower likelihood of receiving preventive health services.10

In conclusion, among the 12 preventive measures identified, we found three differences in receipt of preventive health services by cannabis use status. Current cannabis use does not appear to be associated with significant underuse of preventive services.

Conflicts of interest

Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number R01AG058678. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Footnotes

Financial disclosure

SL Tummalapalli reports that she served as a consultant for Bayer AG. The other authors have nothing to disclose.

Prior poster presentations

  1. Lum E, Tummalapalli SL, Khare M, Keyhani S. Receipt of Preventive Health Services Among Current Cannabis Users. Poster presented at: AHA EPI|Lifestyle Scientific Sessions; March 5, 2020; Phoenix, AZ.
  2. Lum E, Tummalapalli SL, Khare M, Keyhani S. Association of Marijuana Use with Receipt of Preventive Care and Health Behaviors. Poster accepted at: 2020 SGIM Annual Meeting; May 6–9, 2020; virtual.

References

  • 1.National Institutes of Health (NIH). Prevalence of Marijuana Use Among U.S. Adults Doubles Over Past Decade; 2020. [accessed 2020 July 23]. https://www.nih.gov/news-events/news-releases/prevalence-marijuana-use-among-us-adults-doubles-over-past-decade.
  • 2.Steigerwald S, Wong PO, Cohen BE, Ishida JH, Vali M, Madden E, Keyhani S. Smoking, vaping, and use of edibles and other forms of marijuana among U.S. adults. Ann Intern Med. 2018;169(12):890–2. doi: 10.7326/M18-1681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Matsuzaki M, Vu QM, Gwadz M, Delaney JAC, Kuo I, Trejo MEP, Cunningham WE, Cunningham CO, Christopoulos K. Perceived access and barriers to care among illicit drug users and hazardous drinkers: findings from the Seek, Test, Treat, and Retain data harmonization initiative (STTR). BMC Public Health. 2018;18(1):366. doi: 10.1186/s12889-018-5291-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018;43(1):195–212. doi: 10.1038/npp.2017.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Meier MH, Caspi A, Ambler A, Harrington HL, Houts R, Keefe RSE, McDonald K, Ward A, Poulton R, Moffitt TE, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657–E2664. doi: 10.1073/pnas.1206820109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat. 2016;73(3):292–7. doi: 10.1001/jamapsychiatry.2015.3278. [DOI] [PubMed] [Google Scholar]
  • 7.Buckner JD, Heimberg RG, Matthews RA, Silgado J. Marijuana-related problems and social anxiety: the role of marijuana behaviors in social situations. Psychol Addict Behav. 2012;26(1):151–6. doi: 10.1037/a0025822. Epub 2011 Oct 17. [DOI] [PubMed] [Google Scholar]
  • 8.Guo J, Chung IJ, Hill KG, Hawkins JD, Catalano RF, Abbott RD. Developmental relationships between adolescent substance use and risky sexual behavior in young adulthood. J Adolesc Health. 2002;31(4):354–62. doi: 10.1016/s1054-139x(02)00402-0. [DOI] [PubMed] [Google Scholar]
  • 9.Tzilos GK, Reddy MK, Caviness CM, Anderson BJ, Stein MD. Getting higher: co-occurring drug use among marijuana-using emerging adults. J Addict Dis. 2014;33(3):202–9. doi: 10.1080/10550887.2014.950024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chitwood DD, Sanchez J, Comerford M, McCoy CB. Primary preventive health care among injection drug users, other sustained drug users, and non-users. Subst Use Misuse. 2001;36(6–7):807–24. doi: 10.1081/ja-100104092. [DOI] [PubMed] [Google Scholar]

RESOURCES